Nektar Therapeutics (NKTR) Total Non-Current Liabilities (2010 - 2026)

Nektar Therapeutics' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $178.6 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 24.24% year-over-year to $178.6 million; the TTM figure through Mar 2026 stood at $178.6 million (down 24.24% YoY), while the FY2025 annual figure was $181.9 million, down 22.86% from the prior year.
• Total Non-Current Liabilities was $178.6 million for Q1 2026 at Nektar Therapeutics, down from $181.9 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $416.2 million in Q1 2022 to a low of $178.6 million in Q1 2026.
• Historically, Total Non-Current Liabilities has averaged $277.0 million across 5 years, with a median of $262.4 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities slipped 9.01% in 2022, then fell 27.17% in 2023.
• A 5-year view of Total Non-Current Liabilities shows it stood at $336.4 million in 2022, then slipped by 22.0% to $262.4 million in 2023, then decreased by 10.11% to $235.9 million in 2024, then retreated by 22.86% to $181.9 million in 2025, then fell by 1.84% to $178.6 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $178.6 million (Q1 2026), $181.9 million (Q4 2025), and $211.2 million (Q3 2025), per Business Quant data.